Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection

Shopen, Noa; Dekel, Michal; Mizrahi, Michal; Zandberg, Efrat; Talmud, Daniel; Cohen, Neta

doi:10.1016/j.ejim.2022.03.001

Cited by 2 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As per earlier reports, no differences have been found in the occurrence of severe illness outcome between unvaccinated and vaccinated patients who received casirivimab and imdevimab therapy and those who did not [11]. Casirivimab and imdevimab cocktail treatment was associated with lower rates of hospitalization among 403 vaccinated and unvaccinated patients [35].…”

Section: Discussionsupporting

confidence: 64%

“…The delta VOC has caused higher rates of hospitalization than other VOC, even among vaccinated people; thus requiring immediate action to avoid more serious diseases and increased burden on intensive care units (ICUs) [9]. After the second wave of the delta variant, the world was on the verge of entering into a third wave due to the highly divergent VOC omicron [10][11]. The omicron VOC arose in late November 2021, only a few months after the delta VOC was identified, and quickly became the dominant strain globally.…”

Section: Introductionmentioning

confidence: 99%

“…Casirivimab and imdevimab antibody cocktail is a mixture of two neutralizing immunoglobulin gamma-1 (IgG-1) human mAbs against the SARS-CoV-2 spike protein [24]. Casirivimab and imdevimab prevent the virus from infecting host cells by binding to the epitopes of the receptor-binding domain of the SARS-CoV-2 and thereby reducing viral load, shortening the duration of symptoms, reducing the requirement for hospitalization, and lowering the risk of mortality [11,13].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Real-world effect of casirivimab and imdevimab cocktail in patients infected with SARS-CoV-2 delta and omicron variants

Walinjkar¹,

Kumbhar²,

Shinde³

et al. 2023

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: The casirivimab and imdevimab antibody cocktail has proven to be extremely effective against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant. Currently, no data on the clinical outcomes of antibody cocktail with the newer omicron form is available. This retrospective study evaluated the effectiveness of casirivimab and imdevimab antibody cocktail in patients infected with SARS-CoV-2 delta and omicron variants. Methodology: Data of 85 patients of age < 60 years, with comorbid conditions and BMI > 25 kg/m2 were identified from a database of 871 patients. Results: Most of the patients in both delta and omicron groups were administered 600 mg casirivimab + 600 mg imdevimab intravenously. SARS-CoV-2 symptoms started resolving from the 3rd day and by the end of the 14th day most patients in both groups did not report any symptoms. There was no significant difference between delta and omicron group with respect to average symptom onset days, number of hospitalized days post cocktail and number of days post cocktail administration to reverse transcription polymerase chain reaction (RT-PCR) negative status. Forty (58%) patients in the delta group and 16 (94%) patients in the omicron group had the high-resolution computed tomography (HRCT) score of zero. No patient required oxygen support during hospitalization and no mortality was reported. Conclusions: There was no difference in effectiveness and safety of casirivimab and imdevimab antibody cocktail in the patients infected with SARS-CoV-2 delta or omicron.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Introductionmentioning

confidence: 99%